Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$368.42 USD

368.42
284,333

+10.23 (2.86%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $367.63 -0.79 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Edwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up

Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.

Lamb Weston and TTEC Holdings have been highlighted as Zacks Bull and Bear of the Day

Lamb Weston and TTEC Holdings have been highlighted as Zacks Bull and Bear of the Day.

The Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp

BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.

CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?

CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q1.

Boston Scientific (BSX) Q1 Earnings Beat, 2023 View Raised

Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.

Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down

The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.

AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?

AmerisourceBergen's (ABC) fiscal 2023 second-quarter results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

Urmimala Biswas headshot

3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.

LabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline

The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.

Stryker (SYK) to Report Q1 Earnings: What's in the Cards?

Stryker's (SYK) first-quarter results are expected to reflect strong segmental performances. However, rising costs are likely to have continued hurting margins.

Bio-Rad Laboratories (BIO) Stock Sinks As Market Gains: What You Should Know

Bio-Rad Laboratories (BIO) closed the most recent trading day at $461.80, moving -1.17% from the previous trading session.

Will Humana's (HUM) Q1 Earnings Beat on Insurance Unit Strength?

Humana's (HUM) first-quarter results are likely to reflect surging premiums and investment income.

Can Rising Expenses Hurt Teladoc Health's (TDOC) Q1 Earnings?

Teladoc Health's (TDOC) first-quarter results are likely to reflect growth in Access Fees revenues and total visits.

GYN Surgical Sales to Aid Hologic (HOLX) in Q2 Earnings

Strong performance led by MyoSure and NovaSure is expected to have driven Hologic' s (HOLX) Q2 performance.

BioRad Laboratories (BIO) to Post Q1 Earnings: What's in Store?

Bio-Rad Laboratories' (BIO) first-quarter 2023 results are likely to reflect an impressive performance across its Life Science segment, with a gradual reduction in backlogs and an improvement in the supply chain.

DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

DexCom's (DXCM) first-quarter results likely to reflect rising volumes across all channels.

What's in Store for West Pharmaceutical (WST) in Q1 Earnings?

West Pharmaceutical's (WST) first-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?

Robust performance from MyoSure and NovaSure along with increasing contributions from the company's laparoscopic portfolio are expected to have contributed to the Hologic's (HOLX) Q2 reveneus.

IDEXX Laboratories (IDXX) to Post Q1 Earnings: What's in Store?

IDEXX Laboratories' (IDXX) first-quarter 2023 results are expected to reflect an impressive performance in the CAG segment despite inflationary impacts.

Will Lower Managed Care Profits Hurt Centene's (CNC) Q1 Earnings?

Centene's (CNC) first-quarter results are likely to reflect growth in premiums and lower costs.

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

Henry Schein's (HSIC) medical business is expected to have gained from improved U.S. patient traffic to physician offices, ultimate care sites and ambulatory surgical centers.

What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?

Continued demand for the HemoSphere monitoring platform and Smart Recovery is likely to have contributed to the Edwards Lifesciences' (EW) Q1 growth.

Baxter (BAX) to Post Q1 Earnings: What's in the Offing?

Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?

Quest Diagnostics' (DGX) first-quarter 2023 results are likely to reflect an impressive performance in its non-COVID-19 base business amid inflationary pressure and labor challenges.

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.